General Information of Drug (ID: DM7Y4GT)

Drug Name
T-226293 Drug Info
Synonyms
Triparanol; TRIPARANOL; Metasqualene; MER 29; 78-41-1; triparanolum; valip; Metasclene; Clotrox; Triparanolo [DCIT]; Hipocolestina; Acosterina; Drenaren; Diticyl; Triparanol [INN:BAN]; Triparanolum [INN-Latin]; EINECS 201-115-0; NSC 65345; BRN 2064866; 1-(4-(2-Diethylaminoethoxy)phenyl)-1-p-tolyl-2-(4-chlorophenyl)ethanol; CHEMBL187709; 2-p-Chlorophenyl-1-(p-(2-diethylaminoethoxy)phenyl)-1-p-tolylethanol; 1-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(p-tolyl)-2-(p-chlorophenyl)ethanol; NCGC00165907-02
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Preclinical [1]
Cross-matching ID
PubChem CID
6536
ChEBI ID
CHEBI:135714
CAS Number
CAS 78-41-1
TTD Drug ID
DM7Y4GT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-830216 DMCW71N Obesity 5B81 Phase 1 [3]
AZD1979 DMQ1OX4 Obesity 5B81 Phase 1 [4]
PMID25522065-Compound-27 DMXN4KB N. A. N. A. Patented [5]
PMID25522065-Compound-29 DMBNAK9 N. A. N. A. Patented [5]
PMID25522065-Compound-34 DMZDIRQ N. A. N. A. Patented [5]
PMID25522065-Compound-39 DM5YMQH N. A. N. A. Patented [5]
PMID25522065-Compound-40 DMCIQ01 N. A. N. A. Patented [5]
PMID25522065-Compound-11 DM410Z6 N. A. N. A. Patented [5]
PMID25522065-Compound-50 DMBWA0V N. A. N. A. Patented [5]
PMID25522065-Compound-12 DMVKO9C N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diazacholesterol DM5DPM4 Discovery agent N.A. Investigative [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Delta(24)-sterol reductase (DHCR24) TTTK0NH DHC24_HUMAN Inhibitor [2]
Melanin-concentrating hormone receptor 1 (MCHR1) TTX4RTB MCHR1_HUMAN Antagonist [1]

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2 Antilipemic drug-induced skin manifestations. Hautarzt. 1995 Feb;46(2):76-80.
3 2011 Pipeline of Bristol-Myers Squibb.
4 Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
5 Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.